• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Amin I. Kassis, PhD

Professor, Department of Radiology, Harvard Medical School

Director, Radiation Biology and Experimental Radionuclide Therapy Section, Brigham And Women's Hospital

Contact Info

Amin Kassis
Harvard Medical School
200 Longwood Avenue
Boston, MA, 02115
Mailstop: Armenise Bldg, Rm 137
Phone: 617-398-2400
Fax: 617-398-2469
amin_kassis@hms.harvard.edu

Assistant

Not Available.

DF/HCC Program Affiliation

Cancer Risk and Disparities
Cancer Imaging

Lab Website

Kassis-Lab

Research Abstract

The major objective of the research in my laboratories is the development of radionuclide carrier systems suitable for the specific delivery of diagnostic and therapeutic radioactive moieties to cancerous cells. The goal is to maximize the effectiveness of radiotherapeutic agents while minimizing their toxicity to normal tissues. We have synthesized proprietary radiolabeled thymidine analogs (8 US issued patents) and documented their radiodiagnostic and radiotherapeutic potential following locoregional administration in tumor-bearing animals. These results represent promising observations on a novel approach to cancer treatment with unsealed radioactive sources. Pharmacokinetics studies in cancer patients have shown the approach to be equally effective. More recently, we have been developing a proprietary technology (Enzyme-Mediated Cancer Imaging and Therapy, 3 US issued patents, 1 US patent pending, 4 International patents pending) that aim to irreversibly entrap and concentrate diagnostic and therapeutic radionuclides within solid tumors. When labeled with gamma or positron-emitting radionuclides, these molecules enable imaging (SPECT and PET) of solid tumors and their metastases. When labeled with energetic electron- or alpha-particles emitters, these prodrugs deposit therapeutic doses within solid tumors (technology licensed in 2010 by Sabik Medical, Inc.

Most recently, we have also been developing novel proprietary noninvasive blood- (or other bodily fluid) based cancer (and other disease) detection assays (45 US and International pending patents). Using these assays, we have been able to detect cancer-specific signatures (genomic and proteomic) in tumor-bearing mice and in cancer patients. Specifically, these methodologies aim to enable the facile detection of (i) tumors present in an individual prior to the manifestation of pathologic signs and symptoms (screening), (ii) tumors in an individual suspected of having cancer (diagnosis), and (iii) tumor recurrence in an individual undergoing/following various treatments, e.g., radiation/chemo/etc. (technology licensed in 2011 by CellMDx, Inc.).

Publications

View All Publications